On 19 February 2009, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended refusal of the marketing authorisation for the medicinal product Biferonex intended for the treatment of relapsing remitting multiple sclerosis. The company that applied for authorisation was BioPartners GmbH.
Rejected biosimilars: the Biferonex case
Biosimilars/Research
|
Posted 30/07/2009
0
Post your comment
Biferonex is a formulation of recombinant interferon beta-1a glycoprotein expressed by Chinese hamster ovary (CHO) cells transformed with the human interferon beta-1a gene. The amino acid sequence is identical to that of human fibroblast-derived interferon beta-1a and “rather bio(similar)” to other interferon beta-1a products, such as Avonex and Rebif.
However, unlike other similar products, Biferonex is formulated without human serum albumin (Albumin, Human) and is pH-neutral. These aspects are expected to make it less prone to inducing interferon beta-neutralising antibodies, which can limit the effectiveness of treatment. The interferon beta-1a in Bioferonex is (bio)similar, if not identical, to interferon beta-1a originally developed by Bioferon, a prior joint venture of Biogen Corporation, now Biogen Idec, and Rentschler Arzneimittel GmbH & Co.
The effects of Biferonex were first tested in experimental models before being studied in humans. BioPartners presented the results of one main study, in which Biferonex was compared with placebo in 339 adults with relapsing-remitting multiple sclerosis. Each patient received either Biferonex or placebo for two years. The main measure of effectiveness was the reduction in the number of attacks. The company also used information relating to Avonex, and from the published literature on medicines containing interferon beta.
The Committee noted that there were differences between the active substance in Biferonex and other interferon beta-containing medicines available on the market. It therefore concluded that the use of published studies of these interferon beta-containing medicines to support the use of Biferonex was not justified and that studies on Biferonex itself were required. The CHMP was also of the opinion that the results of the clinical study of Biferonex did not show enough evidence that the medicine was effective.
At that point in time, the CHMP was of the opinion that the benefits of Biferonex in the treatment of patients with relapsing-remitting multiple sclerosis did not outweigh its risks and recommended that Biferonex be refused marketing authorisation. BioPartners informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with Biferonex, but that it will request a re-assessment and still wants to accomplish the registration of Biferonex.
Source: EMEA, Biopharma, BioPartners, Scrip
News
FDA approves first eculizumab biosimilar Bkemv for two rare diseases
EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva
General
Boehringer Ingelheim to expand access to adalimumab biosimilar
Challenges and progress in the registration of biosimilars in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
Tocilizumab and pembrolizumab biosimilar advances for Korean firms
Unveiling key clinical findings for denosumab biosimilar candidates
Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
Efficacy and safety of the proposed P043 (Zerafil) vs reference omalizumab in allergic asthma
![147 AA010665 147 AA010665](/var/gabi/storage/images/media/images/147-aa010665/46111-1-eng-GB/147-AA010665_large.jpg)
Biosimilars/Research Posted 09/07/2024
Tocilizumab and pembrolizumab biosimilar advances for Korean firms
![36 AA010641 36 AA010641](/var/gabi/storage/images/media/images/36-aa010641/44274-1-eng-GB/36-AA010641_large.jpg)
Biosimilars/Research Posted 03/07/2024
Unveiling key clinical findings for denosumab biosimilar candidates
![03 AA010722 03 AA010722](/var/gabi/storage/images/media/images/03-aa010722/46138-1-eng-GB/03-AA010722_large.jpg)
Biosimilars/Research Posted 07/05/2024
Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
![Pharmacokinetics 1 V13K15 Pharmacokinetics 1 V13K15](/var/gabi/storage/images/media/images/pharmacokinetics-1-v13k15/20251-1-eng-GB/Pharmacokinetics-1-V13K15_large.jpg)
Biosimilars/Research Posted 16/04/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment